Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Potentially Undervalued?

Let's talk about the popular Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH). The company's shares led the NZSE gainers with a relatively large price hike in the past couple of weeks. The company is now trading at yearly-high levels following the recent surge in its share price. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Today we will analyse the most recent data on Fisher & Paykel Healthcare’s outlook and valuation to see if the opportunity still exists.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Is Fisher & Paykel Healthcare Still Cheap?

According to our valuation model, the stock is currently overvalued by about 23%, trading at NZ$45.37 compared to our intrinsic value of NZ$37.04. Not the best news for investors looking to buy! In addition to this, it seems like Fisher & Paykel Healthcare’s share price is quite stable, which could mean two things: firstly, it may take the share price a while to fall back down to an attractive buying range, and secondly, there may be less chances to buy low in the future once it reaches that value. This is because the stock is less volatile than the wider market given its low beta.

View our latest analysis for Fisher & Paykel Healthcare

Can we expect growth from Fisher & Paykel Healthcare?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Fisher & Paykel Healthcare's earnings over the next few years are expected to increase by 63%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has well and truly priced in FPH’s positive outlook, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe FPH should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping an eye on FPH for a while, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the optimistic prospect is encouraging for FPH, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example - Fisher & Paykel Healthcare has 1 warning sign we think you should be aware of.

If you are no longer interested in Fisher & Paykel Healthcare, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.